Amicus Therapeutics (FOLD), a global biotechnology company focused on developing and commercializing novel medicines for rare diseases, reported a strong start to the year, prompting it to raise its product guidance recently.
The company markets Galafold for Fabry disease and Pombiliti + Opfolda, a two-component therapy, to treat late-onset Pompe disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com